by Madaline Spencer | Feb 13, 2026
Tsewang Tashi, MD, Hematologist at the Huntsman Cancer Institute at the University of Utah, discusses long-term data from the PIONEER clinical trial examining the use of avapritinib in patients with indolent systemic mastocytosis (ISM). Systemic...
by Madaline Spencer | Feb 12, 2026
Robert S. Ohgami, MD, PhD, Professor of Pathology, University of Utah, and Founding Vice President and Chief Medical Director, ARUP Institute for Research and Innovation, discusses the utilization of artificial intelligence (AI) to analyze Castleman disease (CD)...
by Madaline Spencer | Feb 11, 2026
Lynette Chee, PhD, Hematologist at The Royal Melbourne Hospital/ Peter MacCallum Cancer Centre, discusses elritercept’s effect on transfusion independence (TI) in patients with myelodysplastic syndromes (MDS). MDS are a group of blood disorders...
by Madaline Spencer | Feb 10, 2026
February 28 Is Rare Disease Day! Rare Disease Day, observed on the last day of February every year, is a reminder of the challenges faced by those living with a rare disease. Established in 2008 by EURORDIS (The European Organisation for Rare Diseases),...
by Madaline Spencer | Feb 9, 2026
Andrew T. Kuykendall, MD, VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center, discusses 52-week results from the VERIFY clinical trial testing rusfertide in patients with polycythemia vera (PV). PV is a...
